Update on Regulatory Review of Arimoclomol in EU: Orphazyme A/S (ORPH) Nosedives Pre-Market
On February 23, Orphazyme A/S (ORPH) provided an update on the review of the Marketing Authorization Application (MAA) for arimoclomol in the European Union. With a tendency towards denial of the approval, the stock nosedived in the pre-market on Wednesday. The stock remained bullish with a mild gain of 1.51% during the regular trading session […]